Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy.

Arturo CasadevallMichael J JoynerLiise-Anne PirofskiJonathon W SenefeldShmuel ShohamDavid SullivanNigel PanethDaniele Focosi

Published in: Expert review of respiratory medicine (2023)

CCP is safe and effective when used appropriately. Today, most of humanity has some immunity to SARS-CoV-2 from vaccines and infection, which has lessened the need for CCP in the general population. However, COVID-19 in immunocompromised patients is a major therapeutic challenge, and with the deauthorization of all SARS-CoV-2-spike protein-directed monoclonal antibodies, CCP is the only antibody therapy available for this population.

Keyphrases

sars cov
coronavirus disease
respiratory syndrome coronavirus
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
machine learning
binding protein
amino acid
big data
peritoneal dialysis
smoking cessation
stem cells
protein protein
data analysis